for people ages 18-65 (full criteria)
at Irvine, California and other locations
study started
completion around
Principal Investigator
by Tahseen Mozaffar, MD
Headshot of Tahseen Mozaffar
Tahseen Mozaffar



The purpose of this study is to evaluate the safety and tolerability of a single intravenous infusion of AB-1003 in adults diagnosed with limb girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). Participants will be treated in sequential, dose-level cohorts. (Part 1)

Official Title

A Two-part Multicenter Study: a Randomized, Double-blind, Placebo-controlled Dose-escalation Safety Phase (Part 1) Followed by Double-blind, Placebo-controlled, Adaptive Phase (Part 2) Study to Evaluate the Safety and Efficacy of AB-1003 in Adult Subjects With LGMD2I/R9 Mutations in the Gene Encoding Fukutin Related Protein (FKRP)


Limb Girdle Muscular Dystrophy, Limb-Girdle Muscular Dystrophy Type 2, LGMD2I, Muscular Dystrophy, LGMD2, LGMD, FKRP, FKRP Mutation, Fukutin Related Protein, gene therapy, LGMD2I/R9, gene augmentation therapy, Muscular Dystrophies, Limb-Girdle Muscular Dystrophies, AB-1003 dose level 1, AB-1003 dose level 2


You can join if…

Open to people ages 18-65

  1. Male and female subjects aged 18 and 65 years with clinical diagnosis of LGMD2I/R9 and confirmation of FKRP gene mutation.
  2. Ability to ascend 4 stairs between 2.5 and 10 seconds.
  3. Ability to walk/run 10 meters in < 30 seconds.
  4. Able to understand and comply with all study procedures.
  5. Sexually active females of childbearing potential and female and male partners of male subjects receiving AB-1003 must use a barrier method of contraception for the first 6 months after dosing.

You CAN'T join if...

  1. Significant cardiomyopathy as defined by echocardiogram (left ventricular ejection fraction <40%), evidence of conduction defect (increased PR and RR intervals, left bundle branch block and QTcF >480m/sec), NYHA Class 3 or 4 heart failure, or MRI gadolinium enhancement evidence of clinically important myocardial fibrosis.
  2. Contraindication to MRI or hypersensitivity to contrast dyes, shellfish or iodine.
  3. Implanted spinal rods, cardiac pacemaker or other implantation that would distort cardiac MRI images.
  4. History of chronic liver disease (e.g. hepatitis, HIV, steatosis) or abnormal liver function (abnormal GGT and/or abnormal total/direct bilirubin and/or AST and ALT >2 ULN).
  5. Abnormal renal function (GFR < 60 ml/min, using the MDRD equation).
  6. Any life-threatening disease, including malignant neoplasms and medical history or malignant neoplasms within the past 5 years prior to screening (except basal and squamous cell skin cancer).
  7. In the opinion of the investigator, a pre-existing medical condition that predisposes the subject to risks that outweighs the potential benefits.
  8. Requirement for daytime ventilatory support.
  9. Change in glucocorticosteroid treatment within 3 months prior to baseline visit.

    10. Exposure to another investigational drug within 3 months prior to study treatment or

    any previous treatment with gene therapy.

    11. Ongoing participation in any other therapeutic clinical trial. 12. Neutralizing antibody titer to AAV9 ≥ 1:5. 13. Female subjects who are pregnant, plan to become pregnant in the next 12 months, or



  • University of California - Irvine accepting new patients
    Irvine California 92697 United States
  • University of Washington Medical Center accepting new patients
    Seattle Washington 98195 United States

Lead Scientist at UC Irvine

  • Tahseen Mozaffar, MD
    Clinical Professor, Neurology, School of Medicine. Authored (or co-authored) 147 research publications


accepting new patients
Start Date
Completion Date
Asklepios Biopharmaceutical, Inc.
Link to webpage for study and pre-qualification information
Phase 1/2 research study
Study Type
Expecting 10 study participants
Last Updated